Skip to main content
. 2021 Mar 1;12(3):e00315. doi: 10.14309/ctg.0000000000000315

Table 2.

Univariate Cox regression analyses of factors affecting the transplant-free survival in patients with PSC

graphic file with name ct9-12-e00315-g004.jpg

Oslo cohort Helsinki cohort Combined cohort
HR 95% CI P Value N HR 95% CI P Value N HR 95% CI P Value N
Mayo score, per point increase 1.94 1.62–2.32 <0.001 129 2.25 1.26–4.01 0.006 64a 2.11 1.78–2.49 <0.001 193b
ELF test, per point increase 1.80 1.55–2.08 <0.001 138 2.23 1.69–2.94 <0.001 159 2.04 1.80–2.31 <0.001 297
AOM, per point increase 2.56 1.94–3.37 <0.001 128 3.07 1.42–6.62 0.004 64a 2.85 2.20–3.69 <0.001 192c
LnsCD163 3.15 2.19–4.54 <0.001 138 2.89 1.54–5.44 0.001 159 3.82 2.86–5.11 <0.001 297
LnsMR 2.92 1.89–4.52 <0.001 138 1.61 0.70–3.73 0.265 159 2.82 1.88–4.24 <0.001 297
Age, per year increase 1.04 1.02–1.06 <0.001 138
Male, yes vs no 0.68 0.39–1.19 0.177 138
Age at diagnosis, per year increase 1.03 1.01–1.05 <0.001 138
PSC duration, per year increase 1.03 0.99–1.06 0.166 138
IBD status ever, yes vs no 0.55 0.33–0.92 0.024 137
Biliary tract cancer, yes vs no 6.30 3.58–11.09 <0.001 138
Bilirubin 2.16 1.72–2.71 <0.001 130
Albumin, per g/L increase 0.87 0.85–0.91 <0.001 129
ALP 2.29 1.60–3.28 <0.001 130
AST 1.65 1.26–2.15 <0.001 130
ALT 1.21 0.91–1.62 0.184 130
Platelet count 0.66 0.45–0.98 0.039 129
APRI score, per point increase 1.39 1.19–1.63 <0.001 129
INR, per point increase 12.53 3.49–45.00 <0.001 113

All data shown from the Oslo cohort and part of the data from the Helsinki and combined cohort.

a

Calculated in a subset of 64 patients from the Helsinki cohort with available Mayo score and AOM, events n = 12.

b

Calculated in a subset of 193 patients with available Mayo score, events n = 72.

c

Calculated in a subset of 192 patients with available AOM, events n = 72. Bilirubin, ALP, AST, ALT, and platelet count were transformed by the natural logarithm before regression analyses because of a right-skewed distribution.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; AST, aspartate aminotransferase; CI, confidence interval, ELF, enhanced liver fibrosis; HR, hazard ratio; IBD, inflammatory bowel disease; INR, international normalized ratio; LnsCD163, logarithmic transformed soluble CD163; LnsMR, logarithmic transformed soluble mannose receptor; PSC, primary sclerosing cholangitis; sCD163, soluble CD163; sMR, soluble mannose receptor; TRC, platelet count.